Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
CONCLUSION: The choice to treat patients with advanced colorectal cancer using one or the other strategy cannot be based on costs or QoL.
PMID: 30739558 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | France Health | Health Insurance | Health Management | Insurance | Study